Back to Studies

Study analysis · Pain · 2021

You can feel better just by taking sugar pills—even when you know they’re fake.

People with IBS felt way better after taking pills they were told were sugar pills, and it worked just as well as when they didn’t know what they were taking.

Reading level
Moderate certainty
Level 1b · Individual RCT

Overview

What the study found

The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.

In simple terms

This study showed that telling people they're taking a sugar pill (and not hiding it) still helped some people with stomach pain. But it doesn't prove sugar pills work for everyone — just for the kind of people who signed up for this experiment.

What’s the bottom line?

People with IBS took pills they were told were sugar pills, and many felt better—even though they knew the pills had no medicine in them.

How strong is this study?

The researchers used a fair method to randomly assign people to groups, which makes the results trustworthy. But since people knew what they were getting, their expectations might have influenced how they felt — so we can't be 100% sure the pill itself was the only reason they got better.

Reporting

0 / 100

  • COI disclosureconflicts of interest not disclosed
  • Data availabilitydata not shared
  • Code availabilitycode not shared
Methodology

75 / 100

  • Randomization+20/20
  • Blindingnot blinded
  • Control group+15/15
  • Sample size (n=262)+14.6/20
  • Follow-up+10/10
Publication

100 / 100

Statistical

77 / 100

  • P-values+15/15
  • Effect size+20/20
  • Confidence intervalsno confidence intervals
  • Pre-registration+15/15

Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.

Where it sits

RCT reviews

Max 100

Randomized Trials

Max 90

Reviews of Cohort Studies

Max 85

Cohort Studies

Max 72

Reviews of Case-Control Studies

Max 63

Case-Control Studies

Max 58

Cross-Sectional & Case Series

Max 50

Expert Opinion

Max 5
StrongerWeaker
Randomized Trials
Level 1b
65

65 / 100

Probability of being correct

Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.

This design can establish causation. Although this is a randomized controlled trial, the lack of blinding in the open-label placebo group introduces potential performance and detection bias. However, randomization and control groups allow for causal inference between treatment assignment and symptom improvement, especially given the significant differences between OLP and NPC.

No Conflicts

No conflicts of interest identified

No conflicts of interest were disclosed, and the study was funded by NIH with no evidence of industry influence or author financial ties to the outcome.

Funders

National Institutes of Health (NIH)

Conflict Details

multiple authors
Funding

National Institutes of Health (NIH): Funding provided for the study; no other relationships disclosed.

Independent Analysis Safeguards

  • Randomization performed by biostatistician using SAS software
  • Blinded research assistants administered outcome measures
  • Pre-registered protocol and power analysis
  • Modified intent-to-treat analysis with planned sensitivity analysis using MICE

The study was transparently designed and conducted with no industry involvement. The placebo manufacturer (SoftGel Technologies Inc.) is mentioned only as a supplier with no indication of involvement in the study. All authors appear to be affiliated with academic institutions. No financial or non-financial conflicts were disclosed.

Key takeaways

  1. 01

    70% of people taking open-label placebo felt significantly better (50-point drop on symptom scale), same as those taking blinded placebo.

  2. 02

    Those taking no pills improved less (54%).

  3. 03

    Yes—this means a large portion of IBS patients can get real relief from a treatment that doesn’t trick them, which is ethical and could help people who don’t respond to drugs.

Surprising findings

  • Expectation for peppermint oil predicted improvement in the double-blind group—but expectation for placebo did NOT predict improvement in the open-label group.Common belief: placebo effects work because people believe they will. But here, believing in the placebo didn’t help—only believing in peppermint oil did. This suggests the mechanism isn’t general optimism, but specific treatment associations.
  • Open-label placebo was just as effective as double-blind placebo, despite no deception.For over 70 years, medicine assumed deception was essential for placebo effects. This study proves that’s not true—patients improved just as much when fully informed.

Practical takeaways

If you have IBS and haven’t responded to meds, ask your doctor about trying open-label placebo as a complementary therapy—especially if you’re open to non-drug options.

This was tested in moderate-to-severe IBS under strict research conditions. Real-world results may vary, and it’s not a replacement for diagnosing serious conditions.

high confidence

Health coaches and therapists can use the 'honest placebo' script: 'This won’t have medicine, but your brain can still respond to it—try it with an open mind.'

Don’t use this to replace evidence-based care for serious illnesses. It’s best suited for functional disorders with high placebo response rates.

medium confidence

Why this study matters

Placebos Work Even Without Deception

In a 6-week trial with 262 IBS patients, those given open-label placebos (told explicitly they were sugar pills) saw a 90.6-point drop on the IBS Severity Scoring System (IBS-SSS)—nearly double the 52.3-point drop in the no-pill group. The effect was statistically significant (p=0.031) and as strong as the double-blind placebo group (100.3-point drop).

This shatters the long-held belief that placebos only work if you’re tricked. It means doctors could ethically use placebo effects to help patients without lying—opening the door to a new, drug-free treatment option.

70% Got Real Relief—No Drugs Needed

Approximately 70% of patients in both the open-label and double-blind placebo groups achieved a clinically meaningful 50-point reduction in IBS-SSS scores. Only 54% of the no-pill group did. That means for every 10 people with IBS who try open-label placebos, about 7 get life-changing symptom relief.

IBS affects 1 in 10 adults globally, and most treatments are ineffective or come with side effects. This suggests a simple, safe, and ethical intervention could help millions who’ve given up on medicine.

Placebos Had Fewer Side Effects Than 'Real' Placebos

The double-blind placebo group reported 31% adverse events (like reflux or bloating), while the open-label group had only 15.7%. The no-pill group had just 9.3%. This suggests the 'nocebo effect'—expecting side effects—was triggered by blinding, not the pill itself.

It’s ironic: the group told they might be getting a real drug had twice as many side effects as the group told they were getting sugar. This flips the script on how we think about patient expectations and harm.

Want the whole report?

Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.